Inovio announces proposed public offering

Plymouth meeting, pa. , july 2, 2025 /prnewswire/ -- inovio pharmaceuticals, inc. (nasdaq: ino), a biotechnology company focused on developing and commercializing dna medicines to help treat and protect people from hpv-related diseases, cancer, and infectious diseases, today announced that it intends to offer and sell shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof) and in either case, accompanying series a warrants and series b warrants to purchase shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof), in an underwritten public offering.
INO Ratings Summary
INO Quant Ranking